Biobanking 2019
25 September 2019 - 26 September 2019
Examining the evolving technological and commercial landscape to enhance your precision medicine development
With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020, backed by an explosive CAGR of 9.5% between now and 2026. This market growth is fuelled by the increasing drive towards precision and personalised medicine and thus, quality biosamples are now in soaring demand.
Come join us in September 2019 and; thoroughly understand the latest developments in the biobanking industry; network with the industry experts and key opinion leaders; gain insight into how the biobanking industry at the forefront at driving precision medicine and enhancing research and discover ‘Drone4Care’, how drone delivery of biosamples can be a reality.
The event will bring together internationally recognised biorepositories, scientific pioneers from pharmaceutical companies, and academics to strengthen current knowledge in biosample management and their research applications. We will cover the most relevant hot topics including: the latest biorepository technological breakthroughs, the best practices in biobanking, shifts in the biosample regulation landscape, the international biobank societies with ESBB and ISBER, along with a whole host of successful biobanking business model structures to help reinvigorate your biobank.
Copthorne Tara Hotel, London, UK
http://www.biobanking-event.com/DDTwl
SMi’s 10th Annual Biosimilars Conference
25 September 2019 - 26 September 2019
Forecasting future regulatory, commercial & legal challenges to advance biosimilars uptake
SMi Group are delighted to announce the 10th annual Biosimilars Conference taking place on 25th and 26th September 2019. This year’s event will be our first global event taking place in London, UK. The event’s focus is to highlight the current challenges in the biosimilars market and discuss current undergoing plans or developments to overcome these challenges.
The biosimilars market is forecasted to reach USD$23.6B by 2023 at a compound annual growth rate (CAGR) of 31.70%. Factors driving the increase of this market include growing demand for biosimilar drugs due to their cost-effectiveness, growing incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.
With the expiry dates of major patents fast approaching, the emerging gap in the market for biosimilars is now a major attraction for manufacturers. As the availability of biosimilars could potentially reduce direct spending by USD$54B by 2026, the question is what can current biosimilar producing companies do to join this market to benefit the patients, physicians and investors?
Copthorne Tara Hotel, London, UK
http://www.biosimilars-europe.com/drugdiscoverytoday
Discovery Technologies 2019
26 September 2019
Following the success of our inaugral meeting in 2018, ELRIG is pleased to invite you to the 2nd Discovery Technologies meeting to be held at Alderley Park, Macclesfield, UK on September 26th, 2019. This ELRIG meeting, which will be run in collaboration with Alderley Park, will focus on novel and emerging technologies that are improving the efficiency and success rates in the drug discovery process. The two main themes of the conference will be the application of imaging techniques in drug discovery and approaches and technologies used to address early safety assessment within the pharmaceutical industry.
Alderley Park, Cheshire, UK
https://elrig.org/portfolio/2019-discovery-technologies/